• Marimastat Here we studied GLUT targeted nanomedicines as a

  2022-07-13

  

  Here, we studied GLUT1-targeted nanomedicines as a new strategy directed to overcome vascular barrier, enhancing delivery and efficacy in solid tumors. These nanomedicines were prepared by controlled installation of glucose on polymeric micelles incorporating the antitumor agent cisplatin, which is

• br Conclusions Temporally controlled disruption of Gcgr reve

  2022-07-13

  

  Conclusions Temporally-controlled disruption of Gcgr reveals a lack meaningful contribution to the improvement of glycemic control in insulinopenic conditions attributable to the intrinsic loss of GCGR signaling. On the other hand, these data highlight the importance of compensatory systems, incl

• br Materials and methods br Results br Discussion

  2022-07-13

  

  Materials and methods Results Discussion Importantly, we observed that treatment with DA3-CH could reduce the pathophysiological processes in the hippocampal CA1 area after SE. At present, the unimolecular dual incretin receptor agonist has been developed as a treatment for type 2 diabetes,

• Our previous study had shown that silencing FFAR expression

  2022-07-12

  

  Our previous study had shown that silencing FFAR1 expression weakened the action of PIO in increasing insulin secretion in lipotoxic β mass of cl [6]. Resent research found that PIO promoted insulin secretion by upregulating FFAR1 [17]. Therefore, we presumed that FFAR1 may be involved in the anti-

• Focal adhesion kinase Fakir et al

  2022-07-12

  

  Focal adhesion kinase (Fakir et al., 2006), also known as non-receptor tyrosine kinase (PTK2), is a 125-kDa protein that regulates cell migration, adhesion, proliferation, and survival (Tavora et al., 2014; Yang et al., 2016; Tian et al., 2017). Many studies have observed FAK overexpression and/or h

• There are several basic science studies that aim to

  2022-07-12

  

  There are several basic science studies that aim to investigate potential mechanisms behind the reduced incidence of MI in factor Xa inhibitor treated patients. Perzborn et al. reported that in-vitro addition of rivaroxaban reduced tissue-factor induced platelet aggregation (Perzborn, Heitmeier, & L

• It is important to note that histamine H and

  2022-07-12

  

  It is important to note that histamine H1 and H2 receptors are coupled to different G proteins and that their crossinterference induced by histamine H1 and H2 receptor inverse agonists depends on the cointernalization mechanism. To date, histamine H1 and H2 receptor inverse agonist have shown to int

• In the Toc Regulator Mode Fig recognition

  2022-07-12

  

  In the “Toc34 Regulator Mode” (Fig. 6), recognition of the transit peptide by Toc159 monomer (step 4) leads to heterodimer-formation [18]. Subsequently, preprotein interaction with the Toc34G homodimer (step 1) regulates the Toc34G homodimer (step 2, 3). However, this mode requires a parallel induct

• br Materials and methods br Results br Discussion Although t

  2022-07-12

  

  Materials and methods Results Discussion Although there is general agreement that GPR109A has anti-lipolytic activity and that the NEFA reduction in response to nicotinic TAE226 is mediated by GPR109A, whether GPR109A activation has any impact on plasma TG levels is unclear. Since the pheno

• As disclosed in our preceding paper

  2022-07-12

  

  As disclosed in our preceding paper, medicinal chemistry SAR optimization of an HTS hit led to the discovery of , a potent and selective GPR119 agonist. This scaffold differs significantly from the ‘classical’ GPR119 pharmacophore, exemplified by the examples and (). Notably, 66 4 mg lacks an e

• During the structural transition the FD

  2022-07-11

  

  During the structural transition, the FD, the PHD and the TrD retain their tertiary structure. Nevertheless, they undergo large rearrangements in their relative orientation due to secondary changes in hinge segments (R1 to R5) which refold during the low-pH induced conformational change. Particularl

• br Characterization and regional localization

  2022-07-11

  

  Characterization and regional localization of Glu transporters Molecular studies led to the description of five subtypes of plasma membrane Glu transporters termed in accordance to their human or rodent origin (Kanai and Hediger, 1992, Pines et al., 1992, Storck et al., 1992). In humans, these tr

• br Introduction As is now well known obesity

  2022-07-11

  

  Introduction As is now well known, obesity is major risk factor for various diseases such as nonalcoholic fatty liver disease, cardiovascular disease, some cancers (McWilliams and Petersen, 2009), type-2 diabetes mellitus (Jakobsen et al., 2007), and hypertension (Aneja et al., 2004), among other

• br Discussion Our results indicate that marked changes in

  2022-07-11

  

  Discussion Our results indicate that marked changes in the relative distribution of AMPA receptors in microsomal and synaptic fractions occur during the postnatal period, and that these changes are correlated with changes in different populations of AMPA binding sites. At early postnatal ages (PN

• The expression of GLUT receptors throughout the body could

  2022-07-11

  

  The expression of GLUT receptors throughout the body could be considered a potential source for off-target effects even for engineered glucose-conjugated nanomedicines, as there are at least 12 types of GLUT transporters in the body, including GLUT1 in erythrocytes and the blood-brain barrier, as we

15687 records 397/1046 page Previous Next First page 上5页 396397398399400 下5页 Last page